---
title: "TriSalus Life Sciences - CW | 8-K: FY2025 Q2 Revenue: USD 11.21 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252731644.md"
datetime: "2025-08-12T20:05:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252731644.md)
  - [en](https://longbridge.com/en/news/252731644.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252731644.md)
---

# TriSalus Life Sciences - CW | 8-K: FY2025 Q2 Revenue: USD 11.21 M

Revenue: As of FY2025 Q2, the actual value is USD 11.21 M.

EPS: As of FY2025 Q2, the actual value is USD -0.27.

EBIT: As of FY2025 Q2, the actual value is USD -6.837 M.

### Segment Revenue

-   TriSalus Life Sciences reported $11.2 million in revenue for the second quarter of 2025, marking a 52% increase year-over-year and a 22% growth quarter-over-quarter, driven by increased selling resources and market share expansion.

### Operational Metrics

-   Gross margins were 84% in the second quarter, down from 88% in the same period of 2024, due to lower manufacturing efficiency associated with newly launched products.
-   Research and Development expenses decreased to $3.9 million from $4.7 million in the same quarter of the prior year, primarily due to reduced clinical trial costs for Nelitolimod.
-   Sales and Marketing expenses increased to $7.2 million from $6.0 million, reflecting continued investment in commercial expansion.
-   General & Administrative expenses rose to $5.7 million from $4.0 million, mainly due to increased professional services costs.
-   Operating losses were reduced to $7.3 million from $8.2 million in 2024, attributed to decreased R&D expenses.
-   Net loss attributable to common stockholders was $9.0 million, compared to $5.1 million in 2024, primarily due to non-cash adjustments to the fair value of contingent earnout liability.

### Cash Flow

-   As of June 30, 2025, cash and cash equivalents totaled $26.5 million, providing sufficient runway to reach positive adjusted EBITDA in the first half of 2026.

### Unique Metrics

-   Adjusted EBITDA losses were $5.3 million, compared to losses of $6.7 million for the same period in 2024, due to increased sales, reduced R&D expenses, and increased stock compensation.

### Outlook / Guidance

-   TriSalus Life Sciences reaffirmed its full-year revenue growth guidance of 50%, driven by increasing market penetration within liver-directed therapies and continued commercial momentum.

### Related Stocks

- [TLSIW.US](https://longbridge.com/en/quote/TLSIW.US.md)

## Related News & Research

- [Oil drops on lower demand forecasts despite deadlock in US-Iran talks](https://longbridge.com/en/news/295727368.md)
- [Novo CEO says obesity market won't be winner-take-all battle with Lilly](https://longbridge.com/en/news/295777893.md)
- [Elon Musk's Tesla Weighs $10.1 Billion Solar Plant, Chamath Palihapitiya Calls It a Bet on Nuclear: Here's Why](https://longbridge.com/en/news/295754346.md)
- [CoreWeave and Nebius Group Deliver Earnings Shocker. Here's What It Signals About the Future of AI.](https://longbridge.com/en/news/295703122.md)
- [Dan Ives Says CoreWeave, Cisco Earnings ‘Pieces of the Puzzle’ for AI Trade: ‘Get the Popcorn Out’](https://longbridge.com/en/news/295693267.md)